Sorafenib in metastatic MTC – a case report and minireview of the literature

Case report

(1686) Views  (555) Full article downloads

Authors: Mila Petrova, Zhasmina Mihaylova, Albena Fakirova

Published Date May 2010 Volume 2010:3 Pages 55 - 58

DOI: http://dx.doi.org/10.2147/IMCRJ.S9384

Mila Petrova¹, Zhasmina Mihaylova¹, Albena Fakirova²

¹Hematology and Oncology Department, ²Pathology Department, Medical Military Academy, Sofia, Bulgaria

Abstract: Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.

Keywords: medullary thyroid cancer, tumor response, cardiotoxicity, TKIs

Other articles by Dr Milla Petrova